Timo Joensuu

Medicine · Health Sciences

23h-index3.9kcitations118works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Prostate Cancer Treatment and Research(41), Virus-based gene therapy research(34), Cancer Research and Treatments(29), Radiopharmaceutical Chemistry and Applications(24), Viral Infectious Diseases and Gene Expression in Insects(22)

Publications118 total

Supplementary Figure Legend from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
2023Open Access
Data from Oncolytic Adenovirus ICOVIR-7 in Patients with Advanced and Refractory Solid Tumors
2023Open Access
Supplementary Figure 1 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
2023Open Access
Supplementary Table 2 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
2023Open Access
Supplementary Figure 4 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
2023Open Access
Supplementary Table 3 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
2023Open Access
Supplementary Figure 4 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
2023Open Access
Supplementary Figure 1 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
2023Open Access
Supplementary Figure Legend from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
2023Open Access
Supplementary Figure 2 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
2023Open Access
Supplementary Table 1 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
2023Open Access
Supplementary Figure 2 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
2023Open Access
Supplementary Data from Oncolytic Adenovirus ICOVIR-7 in Patients with Advanced and Refractory Solid Tumors
2023Open Access
Supplementary Figure 5 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
2023Open Access
Data from Oncolytic Adenovirus ICOVIR-7 in Patients with Advanced and Refractory Solid Tumors
2023Open Access
Supplementary Figure 3 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
2023Open Access
Supplementary Figure 5 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
2023Open Access
Supplementary Table 2 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
2023Open Access
Data from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
2023Open Access
Supplementary Table 3 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
2023Open Access
page 1 of 6Next →

Frequent Co-authors

Kalevi Kairemo(16), Timo Kiljunen(12), Aki Kangasmäki(9), Akseli Hemminki(8), Pentti Tuohimaa(8), ­Eero Pukkala(6), Finn Edler von Eyben(6), Hans H. Storm(5), Eric J. Holowaty(5), Mary Gospodarowicz(5), Heikki Joensuu(5), Timo Ylikomi(5), Kaarina Partanen(5), Lois B. Travis(4), Charles F. Lynch(4), Michael Andersson(4), Bengt Glimelius(4), Petteri Hervonen(4), Tiina Luukkaala(4), Irene Virgolini(4)